For those following the development of retatrutide with a view to future use, it is worth noting that NICE guidance on obesity pharmacotherapy including its technology appraisal of semaglutide (Wegovy) for weight management does not specify a preferred time of day for weekly injectable agents
& Brito, J
The AACE/ACE, in contrast to the ADA, provides several monotherapy options that are recommended in the following order according to the strength of each recommendation: metformin, GLP-1 receptor agonist, SGLT-2 inhibitor, DPP-4 inhibitor, thiazolidinedione, -glucosidase inhibitor, and an insulin secretagogue (a sulfonylurea or meglitinide)
Novo was first in the market,got CMS Medicare approval with Narrow Pipeline of Drugs only on Weight loss & Diabetes (Front runner Semaglutide) Lilly has better Efficacy Drug(Tirzepatide & Pipeline drugs) for Wt loss/Diabetes,Longer IP Patent Runway till mid 2030s with better Growth Penetration With Wider Pipeline of Pharma drugs including Oncology/ Neurology/ Immunology/ Inflammation,Urology- Erectile Dysfunction,Osteoporosis in Men and Women and afford to run the price war with Novo and wipeout their Business Eli Lilly is winning hands down
